Literature DB >> 1683918

Obstructive sleep apnoea in patients with dilated cardiomyopathy: effects of continuous positive airway pressure.

S Malone1, P P Liu, R Holloway, R Rutherford, A Xie, T D Bradley.   

Abstract

The combined effects of negative intrathoracic pressure swings during obstructive sleep apnoeas (OSAs) and increased sympathetic nervous system tone associated with hypoxia and sleep arousal may lead to pulmonary oedema or left-ventricular hypertrophy. Therefore, we have done a study of patients with congestive heart failure secondary to idiopathic dilated cardiomyopathy to see whether OSA could contribute to impaired left-ventricular function and to assess nasal continuous positive airway pressure (NCPAP) for treatment. Eight men (aged 29-69 years) took part in the study; all were obese. Left-ventricular ejection fraction (LVEF) was measured while on stable medication and then 4 weeks after the start of nocturnal NCPAP. NCPAP was associated with abolition of OSA (mean [SE] number of apnoeas and hypopnoeas per hour of sleep 54.1 [7.2] and 1.0 [0.4] for pretreatment and NCPAP nights, respectively, p less than 0.0001). Mean (SE) LVEF increased from 37 (4)% pretreatment to 49 (5)% after four weeks' NCPAP therapy (p less than 0.0001). Withdrawal of NCPAP for 1 week in four patients was associated with a reduction in LVEF from 53 (6)% to 45 (5)% (p less than 0.001). OSA may contribute to impaired left-ventricular function in some patients with dilated cardiomyopathy of otherwise unknown origin, and reversal of OSA by NCPAP can lead to significant improvement in LVEF.

Entities:  

Mesh:

Year:  1991        PMID: 1683918     DOI: 10.1016/0140-6736(91)92299-h

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  50 in total

1.  Continuous positive airway pressure for congestive heart failure.

Authors:  T D Bradley
Journal:  CMAJ       Date:  2000-02-22       Impact factor: 8.262

Review 2.  Prognosis and sleep disordered breathing in heart failure.

Authors:  I Wilcox; S G McNamara; T Wessendorf; G N Willson; A J Piper; C E Sullivan
Journal:  Thorax       Date:  1998-10       Impact factor: 9.139

Review 3.  Impact of treatment of sleep apnoea on left ventricular function in congestive heart failure.

Authors:  M T Naughton
Journal:  Thorax       Date:  1998-10       Impact factor: 9.139

Review 4.  Treatment options for sleep apnoea.

Authors:  R R Grunstein; J Hedner; L Grote
Journal:  Drugs       Date:  2001       Impact factor: 9.546

5.  The impact of positive airway pressure on cardiac status and clinical outcomes in patients with advanced heart failure and sleep-disordered breathing: a preliminary report.

Authors:  Apostolos Karavidas; Fotis Kapsimalis; George Lazaros; Evaggelos Markozanes; Sophia Arapi; Kiriaki Cholidou; Vassiliki Matzaraki; Konstantina Kyrkou; Dimitris Tsiachris; Evaggelos Matsakas; Vlassios Pyrgakis; Manos Alchanatis
Journal:  Sleep Breath       Date:  2010-10-02       Impact factor: 2.816

Review 6.  Sleep.7: positive airway pressure therapy for obstructive sleep apnoea/hypopnoea syndrome.

Authors:  P Gordon; M H Sanders
Journal:  Thorax       Date:  2005-01       Impact factor: 9.139

7.  Effect of treatment by nasal CPAP on cardiopulmonary exercise test in obstructive sleep apnea syndrome.

Authors:  Ching-Chi Lin; Ching-Kai Lin; Kun-Ming Wu; Chon-Shin Chou
Journal:  Lung       Date:  2004       Impact factor: 2.584

Review 8.  Sleep-disordered breathing and cardiovascular disorders.

Authors:  Rohit Budhiraja; Pooja Budhiraja; Stuart F Quan
Journal:  Respir Care       Date:  2010-10       Impact factor: 2.258

Review 9.  Predicting survival in heart failure.

Authors:  Viorel G Florea; Inder S Anand
Journal:  Curr Cardiol Rep       Date:  2007-05       Impact factor: 2.931

Review 10.  Obstructive Sleep Apnea in Heart Failure: Review of Prevalence, Treatment with Continuous Positive Airway Pressure, and Prognosis.

Authors:  Himad K Khattak; Faisal Hayat; Salpy V Pamboukian; Harvey S Hahn; Brian P Schwartz; Phyllis K Stein
Journal:  Tex Heart Inst J       Date:  2018-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.